Molecular Subtypes of Endometrial Cancer

Panelists discuss how molecular testing has revolutionized the way clinicians categorize endometrial cancer, leading to a deeper understanding of disease biology and treatment personalization. They explain how advances in genomic profiling allow tumors to be classified into distinct molecular subtypes—such as POLE-ultramutated, mismatch repair–deficient, p53-abnormal, and no specific molecular profile. This framework moves beyond traditional histopathologic assessment, providing a more precise way to predict prognosis and guide therapeutic decisions.

The conversation explores how identifying these molecular categories can inform the likelihood of recurrence, response to therapy, and eligibility for targeted or immunotherapy approaches. Panelists emphasize that molecular testing is now becoming standard practice, allowing oncologists to move toward individualized care pathways rather than one-size-fits-all treatment plans. They highlight how these classifications are influencing ongoing research, clinical trial design, and guideline recommendations across multiple cancer care settings.

Finally, the discussion focuses on practical implementation, including testing accessibility, turnaround time, and integration into community practice. The panel underscores the importance of multidisciplinary collaboration between pathologists, oncologists, and genetic specialists to ensure molecular results are interpreted accurately and translated effectively into patient management strategies.